Evidence and Research

Trials have shown that daily oral PrEP works if taken correctly and consistently. But there’s still a lot to learn about new PrEP agents and how to deliver oral PrEP.


PrEP research today spans implementation research on delivering daily oral tenofovir-based PrEP and clinical trials of new agents, including vaginal ARV-containing rings and long-acting injectables. Policy and program decisions are guided by data from the original randomized clinical trials as well as newer studies. There are many moving pieces and many product types.

No single PrEP option—and no single prevention option—is right for all people, or for any one person all the time. Demonstration projects are providing information about what's available, even as research continues for additional options.

Read below to find out more about:

Clinical Trials Evidence
Open Label and Demonstration Project Evidence
Ongoing Research

News Spotlight

  • PrEPcost.org Launches

    November 8, 2017

    This site matches individuals who are interested in PrEP to eligible health plans and provides comparative pricing. PrEPcost.org is designed for both PrEP users and health care providers to make it easy to navigate the insurance options and find the best plans available.

    Read more

  • Health Dept to Place New HIV Prevention at Uni

    September 26, 2017

    iafrica.com reports on a decision by South Africa’s Department of Health to roll out PrEP to its university system. An initiative of the Higher Education and Training HIV/AIDS Programme (HEAIDS) is making PrEP available to students for the first time. PrEP will be available in 11 clinics at seven universities. Up to now, government programs have been aimed at reaching sex workers and men who have sex with men.

    Read more